Skip to main content
OpenTrials
Completed

NCT Number: NCT02030912

Effect of Minocycline & Amoxicillin on Antibiotic Resistant Bacteria and Indigenous Microbiotas

A randomised, open labelled study design is selected in order to determine the emergence and persistence of antibiotic resistant bacteria in humans and on the composition of the indigenous microbiotas at various body sites. These will involve the administration to volunteers of minocycline and amoxicillin- a control group will receive a placebo. Microbiology of the skin, saliva, faecal, skin and nasal micro flora, safety and adverse events, vital signs, will be evaluated. The objectives of metagenomic analysis are:

* To identify the in vivo molecular mechanisms responsible for antibiotic resistance and its transfer in the indigenous oral and faecal microbiotas using metagenomics resistome analysis. * To determine the impact of the use of antimicrobial agents on the oral resistome * To determine the impact of the use of antimicrobial agents on the faecal resistome * To determine the ecological impact of the use of antimicrobial agents on the relative abundance of phylotypes of the indigenous oral microbiota * To determine the ecological impact of the use of antimicrobial agents on the relative abundance of phylotypes of the indigenous faecal microbiotas

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Richmond Pharmacology Ltd

London, SW17 0RE,, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women aged between 18 and 40 years.
  • Following verbal & written information about the trial, the subject has signed & dated informed consent before any study related activity was carried out.
  • Subject legally competent and able to communicate effectively with the study personnel
  • Normal finding in the medical history and physical examination, unless the investigator considers an abnormality to be clinically irrelevant.
  • Male or female subjects who are using a medically acceptable method of contraception or of non-childbearing potential (i.e., surgically sterile-bilateral tubal ligation or removal of both ovaries and/or uterus at least 6 months prior to dosing or naturally postmenopausal for at least one year with a Screening FSH leve≥l 40 mIU/L). - - A negative serum pregnancy test is required at Screening for females.

Exclusion criteria

  • Regular use of medication, except contraceptive, vitamin tablets, treatment with antimicrobial agents within the 3 months preceding the study, Use of antibiotics for 4 weeks prior to the study drug application or use of concomitant systemic or topical antibiotics, Systemic treatment with immunosuppressive drugs e.g. cyclosporine, azathioprine or oral corticosteroids within 4 weeks prior to baseline visit (Visit 2) .
  • Participation in a trial with another investigational drug within the 3 months preceding the study
  • Present or residual gastrointestinal, renal insufficiency or hepatic disorder
  • Abnormal pathology of nasal passages
  • Any clinically significant allergy or drug intolerance
  • Active hay fever, on-going cold/flu symptoms, including rhinitis at baseline (visit 2)
  • Any medical history of renal insufficiency or hepatic disorder or other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs
  • history of hypersensitivity to beta-lactams or tetracycline
  • pregnant or breast-feeding women
  • Subjects known or suspected of not being able to comply with trial protocol (e.g. alcoholism, drug dependency, or psychological state). History of regular alcohol consumption exceeding an average weekly intake of alcohol greater than 21 units for female and 28 units for male.

One unit is equivalent to a half-pint of beer or one measure of spirits or one glass of wine.

  • Subjects with known or suspected immunodeficiency.

Treatment and study plan

3 doses of amoxicillin daily for 7 days

Drug

2 doses of minocycline daily for five days

Drug

2 doses of placebo daily for five days

Other

Primary outcomes

  1. Percentage of resistant bacteria collected from body sites in subjects receiving minocycline/ amoxicillin compared to the baseline.

    Time frame: 12 Months

Secondary outcomes

  1. Adverse events (AEs) will be monitored throughout the study

    Time frame: 12 Months

Sponsors and collaborators

Lead sponsor

Helperby Therapeutics Ltd

Industry

Collaborators

  • Richmond Pharmacology Limited

Registry information

Official study title

Phase 4 Study Into the Effect of Minocycline and Amoxicillin Administration of the Prevalence of Antibiotic Resistant Bacteria and on the Indigenous Oral, Faecal, Cutaneous and Nasal Microbiotas

Acronym: ANTIRESDEV

Important dates

Study start
2009
Primary completion
2012
Study completion
2013
First posted
Jan 9, 2014
Registry last updated
Jan 9, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.